News Headlines Article

GlaxoSmithKline returns rights to 3 Anacor drug targets, expands deal on another
San Francisco Business Times

GlaxoSmithKline plc will return the rights to three drug targets to Anacor Pharmaceuticals Inc. but pay $5 million up front as it expands the deal around drugs zeroing in on a bacterial enzyme, malaria and tuberculosis. Palo Alto-based Anacor (NASDAQ: ANAC) said the new deal could land another $11.3 million in milestone and research funding by the end of 2012. The original October 2007 deal allowed GSK to select drugs from four targets, including the bacterial enzyme leucyl-tRNA synthetase, or LeuRS.